 | CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab - Yahoo Finance finance.yahoo.com - March 5 at 6:50 PM |
 | CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab finance.yahoo.com - March 5 at 6:50 PM |
 | CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and Brazil finance.yahoo.com - March 5 at 6:50 PM |
 | CytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement - GlobeNewswire globenewswire.com - March 4 at 1:39 AM |
 | CytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement - Yahoo Finance finance.yahoo.com - March 3 at 8:39 PM |
 | CytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement finance.yahoo.com - March 3 at 8:39 PM |
 | CytoDyn (OTCMKTS:CYDY) Trading Down 6.3% americanbankingnews.com - February 24 at 12:18 AM |
 | CytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients - Yahoo Finance finance.yahoo.com - February 23 at 1:27 AM |
|
 | CytoDyn in discussions with regulators after CD12 data in COVID-19 - Seeking Alpha seekingalpha.com - February 22 at 3:20 PM |
 | CytoDyn in Discussions with U.S. FDA, MHRA and Health Canada After Unblinding its CD12 Trial Data for Severe-to-Critically Ill COVID-19 Patients - GlobeNewswire globenewswire.com - February 22 at 10:20 AM |
 | CytoDyn: Reliable In All The Wrong Places - Seeking Alpha seekingalpha.com - February 21 at 11:02 PM |
 | CytoDyn investors, executives reach settlement agreement in shareholder suit - Portland Business Journal bizjournals.com - February 1 at 6:44 PM |
 | Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use - Yahoo Finance finance.yahoo.com - January 30 at 12:05 AM |
 | Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn's Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use - GlobeNewswire globenewswire.com - January 29 at 7:05 PM |
 | Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use finance.yahoo.com - January 29 at 7:05 PM |
 | ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CytoDyn Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - Yahoo Finance finance.yahoo.com - January 27 at 5:48 PM |
 | ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CytoDyn Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm finance.yahoo.com - January 27 at 5:48 PM |
 | FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 - PRNewswire prnewswire.com - January 23 at 7:19 AM |
 | CytoDyn Inc (CYDY) Price Targets From Analysts stocknews.com - January 14 at 4:25 PM |
 | REMINDER: CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries - GlobeNewswire globenewswire.com - January 4 at 8:50 AM |
 | REMINDER: CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries feeds.benzinga.com - January 4 at 6:11 AM |
 | FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn's Phase 3 Trial for Severe-to-Critical COVID-19 Patients - GlobeNewswire globenewswire.com - December 31 at 2:41 PM |
|
 | CytoDyn Announces Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity - GlobeNewswire globenewswire.com - December 31 at 4:40 AM |
 | FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients finance.yahoo.com - December 31 at 4:40 AM |
 | CytoDyn Announces Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity finance.yahoo.com - December 31 at 4:40 AM |
 | CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries - Yahoo Finance finance.yahoo.com - December 30 at 5:19 PM |
 | CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries - GlobeNewswire globenewswire.com - December 30 at 7:18 AM |
 | CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries finance.yahoo.com - December 30 at 7:18 AM |
 | CytoDyn to amend Phase 3 trial protocol for COVID-19 therapy - Seeking Alpha seekingalpha.com - December 27 at 6:57 PM |
 | Breakingviews - Pandemic pet boom keeps running for new top dogs - Nasdaq nasdaq.com - December 25 at 1:57 PM |
 | FDA Provides Guidance for Adding an Open-Label Extension to CytoDyn's Phase 3 Trial for Severe-to-Critical COVID-19 Patients Until Trial Data is Unblinded - GlobeNewswire globenewswire.com - December 24 at 11:59 PM |
 | FDA Provides Guidance for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients Until Trial Data is Unblinded finance.yahoo.com - December 24 at 11:59 PM |
 | FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial - GlobeNewswire globenewswire.com - December 22 at 8:53 AM |
 | FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn’s Phase 3 Trial finance.yahoo.com - December 22 at 8:53 AM |
 | CytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study - Yahoo Finance finance.yahoo.com - December 16 at 8:29 PM |
 | CytoDyn Inc.: Understanding Leronlimab And HIV - Seeking Alpha seekingalpha.com - December 16 at 3:28 PM |
 | CytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19 - GlobeNewswire globenewswire.com - December 15 at 6:06 PM |
 | CytoDyn Completes Enrollment for Phase 3 Registrational Trial for 390 Patients with Severe-to-Critical COVID-19 finance.yahoo.com - December 15 at 6:06 PM |
 | CytoDyn (CYDY) Enrolls First Patient in NASH Study on Leronlimab - Nasdaq nasdaq.com - December 3 at 11:14 PM |
 | CytoDyn to Hold Webcast on December 10 to Update Clinical and Regulatory Developments - GlobeNewswire globenewswire.com - December 3 at 6:13 PM |
 | CytoDyn to Hold Webcast on December 10 to Update Clinical and Regulatory Developments finance.yahoo.com - December 3 at 6:13 PM |
 | CytoDyn Announces First Patient Enrolled in Phase 2 Trial for NASH - GlobeNewswire globenewswire.com - December 2 at 8:37 AM |
 | CytoDyn Announces First Patient Enrolled in Phase 2 Trial for NASH finance.yahoo.com - December 2 at 8:37 AM |
 | CytoDyn Inc. barrons.com - November 27 at 10:52 PM |
 | CytoDyn Announces Partnership with amfAR to Accelerate HIV Cure Research - GlobeNewswire globenewswire.com - November 23 at 6:43 PM |
 | CytoDyn Announces Partnership with amfAR to Accelerate HIV Cure Research finance.yahoo.com - November 23 at 6:43 PM |
 | CytoDyn reaches target enrollment for second interim analysis of Phase 3 COVID-19 trial - Seeking Alpha seekingalpha.com - November 23 at 8:40 AM |
 | CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This Year - Yahoo Finance finance.yahoo.com - November 23 at 8:40 AM |
 | CytoDyn Reaches Enrollment Target of 293 Patients for 2nd DSMC Interim Analysis of Phase 3 COVID-19 Trial and Expects to Enroll the Remaining 97 Patients in the Next Few Weeks to Complete the Trial This Year finance.yahoo.com - November 23 at 8:40 AM |
 | CytoDyn Files Protocol With FDA For Phase2 Trial For COVID-19 Patients With Long-Hauler Symptoms - Nasdaq nasdaq.com - November 17 at 5:51 PM |